Pharmacokinetic and pharmacodynamic studies form an important foundation for drug development by profiling therapeutic agents and their effects across multiple timepoints. Unfortunately, PK/PD protein measurements are often limited by plate or bead-based methods with narrow dynamic range, relatively large volume requirements, and long assay times. These factors restrict both the quantity and the quality of proteomic data that can be collected from cell-based or animal models. Correlia offers an automated platform to overcome these bottlenecks - enabling highly efficient protein measurements from as little as 2 microliters of a diluted biosample. In this webinar, we focus on case studies in therapeutic antibody development. Both general and specific measurements of monoclonal antibodies are made possible, respectively based upon IgG-generic and ligand-specific binding affinities.
Protein concentrations can be measured in a fraction of the time and sample volume required for conventional immunoassays.
Targets are measured in a “sample-in, answer-out” workflow with minimal user intervention.
Correlia measurements demonstrate extended dynamic range when validated against competing immunoassays.